MedTrace Logo

Ivabradine for Heart Rate Reduction During Exercise in Healthy Adults

NCT07717710 · Status: NOT_YET_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-07-22

No results posted yet for this study

Summary

During exercise, working muscles require more oxygen. The heart meets this demand in two ways: by beating faster (heart rate) and by pumping more blood with each beat (stroke volume). Heart rate increases steadily with exercise intensity until exhaustion, but the amount of blood pumped with each beat tends to plateau at moderate intensities. Why the amount of blood pumped with each beat becomes limited before heart rate, however, is not well understood.

Studying these mechanisms is difficult because most drugs that lower heart rate also affect how strongly the heart pumps, making it hard to separate the two effects. One medication that can help with this is ivabradine, which is used to treat people with heart disease who have high resting heart rates. It slows the heart rate without changing how strongly the heart pumps.

This study will investigate whether ivabradine lowers heart rate during exercise in healthy younger and older adults, and whether a higher dose lowers heart rate more. The results will help us better understand how heart rate influences the heart's ability to supply oxygen to the body during exercise, and what limits the ability to exercise as people age.

Participants will:

* Attend three visits at SportsCardiologyBC in Vancouver
* Complete a cycling exercise test at each visit to measure heart rate and how hard they can exercise
* Take ivabradine (a heart-rate-lowering medication) before the exercise test at Visits 2 and 3 (a lower dose at Visit 2 and a higher dose at Visit 3)
* Be monitored for side effects including slow heart rate, visual symptoms, and headache.

Conditions

  • Healthy Adult

Interventions

DRUG

Ivabradine (single oral dose)

A single oral dose of ivabradine is administered at each experimental visit, in a fixed order: 7.5 mg at Visit 2 (one 7.5 mg tablet), and 12.5 mg at Visit 3 (one 7.5 mg + one 5 mg tablet). Ivabradine is a selective hyperpolarization-activated cyclic nucleotide-gated transmembrane (HCN4) channel inhibitor that reduces heart rate without affecting myocardial contractility.

Sponsors & Collaborators

  • University of British Columbia

    lead OTHER

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-08-01
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07717710 on ClinicalTrials.gov